Daniela Isabel Abbrescia
@libero.it
Scopus Publications
- Acidosis Drives Vasculogenic Mimicry in PDAC CSCs via Na+/H+ Exchanger Isoform 1 (NHE1) and Calcium Entry
Maria Raffaella Greco, Francesca Fracasso, Stefania Cannone, Daria Di Molfetta, Marilena Ardone, Sharon Natasha Cox, Brunella Rita Ladogana, Daniela Isabel Abbrescia, Apollonia Tullo, Marianna Ranieri, Stephan J. Reshkin, Rosa Angela Cardone
Cells, 2026
Vasculogenic mimicry (VM) is the ability of cancer stem cells (CSCs) to express an endothelial-like phenotype and participate in tumor neovascularization via the formation of a blood-conducting, matrix-rich network. We previously reported that pancreatic ductal adenocarcinoma (PDAC) CSCs develop their VM phenotype via two interacting and coordinated factors that support the formation of the VM network: (i) the overexpression of genes for endothelial factors and vascular receptors and (ii) the very high secretion of numerous pro-angiogenic/growth factors. While microenvironmental acidosis (low pHe) is an important driver of tumor metastasis, especially in PDAC, and is a component of the CSC niche, its role in VM and the ion transporters involved remains unknown. As normal stem cell differentiation is regulated by Na+/H+ exchanger 1 (NHE1)-driven pH, we investigated the role of NHE1 and the intracellular signaling involved in the acidosis-induced VM using a platform of 3D organotypic cultures composed of Matrigel with increasing concentrations of Collagen I. VM was highest on 90% Matrigel:10% Collagen I, representative of an early tumor ECM, and it decreased with increasing concentrations of Collagen I, representative of advanced tumors. In all ECM compositions, VM capacity increased stepwise with pHe acidification, and both basal and acid-stimulated VM were dependent on NHE1 activity. Acidification also decreased resting pHi and increased NHE1 proton extrusion activity, NHE1/ß1 integrin co-expression, and intracellular Ca2+. The stimulation of VM by extracellular acidosis depended on the transport of extracellular Ca2+ into the cell and the consequent increase in intracellular Ca2+. Altogether, these data demonstrate that extracellular acidification triggers cellular mechanisms that upregulate VM to overcome the constraints imposed by ECM composition, thereby permitting VM in ECMs where this phenotype is not expressed and extending the VM phenotype towards the tumor center to further drive metastasis. - Polydatin reactivates mitochondrial bioenergetics and mitophagy while preventing premature senescence by modulating microRNA-155 and its direct targets in human fibroblasts with trisomy 21
Daniela Valenti, Daniela Isabel Abbrescia, Flaviana Marzano, Giampietro Ravagnan, Apollonia Tullo, Rosa Anna Vacca
Free Radical Biology and Medicine, 2025
Mitochondrial dysfunction and redox dyshomeostasis are considered crucial factors causally linked to the pathogenesis of Down syndrome (DS), a human genetic anomaly currently lacking a cure, associated with neurodevelopmental deficits in children and early onset symptoms of aging in adults. Several natural plant-derived polyphenolic compounds, known for their neurostimulator, antioxidant and anti-inflammatory activities, have been proposed as dietary supplements to manage DS-linked phenotypic alterations. However, the poor bioavailability and rapid metabolism of these compounds have limited conclusive evidence regarding their clinical efficacy in individuals with DS. Polydatin (PLD), a natural polyphenolic glucoside precursor of resveratrol derived from Polygonum cuspidatum , is instead highly bioavailable and resistant to enzymatic oxidation. PLD supplementation has shown many therapeutic efficacies in several human diseases without side effects. In this study, we used fetal trisomy 21 human skin fibroblasts (DS-HSFs) to investigate, from a mechanistic point of view, whether PLD supplementation could prevent or counteract critical cellular alterations linked to both neurodevelopmental deficits and early aging in DS. Our findings demonstrate that PLD reactivates mitochondrial bioenergetics, reduces oxygen radical overproduction and prevents oxidative stress (OS)-induced cellular senescence and DNA damage in DS-HSF. Notably, we identified a novel mechanism of PLD action involving the chromosome-21-encoded microRNA-155 (miR-155) and its direct target genes casitas B-lineage lymphoma (CBL), BAG Cochaperone 5 (BAG5) and mitochondrial transcription factor A ( TFAM). These proteins play pivotal roles in regulating mitochondrial bioenergetics, biogenesis and mitophagy. Given that the deregulation of miR-155/CBL axis is also implicated in acute leukemias, which frequently occur in children with DS, PLD emerges as a promising candidate for translational application. Its ability to enhance mitochondrial bioenergetics and address critical DS-associated phenotypic alterations highlights its therapeutic potential. • Polydatin (PLD) improves mitochondrial bioenergetics and mitophagy in T21 fibroblasts. • PLD prevents ROS overproduction, oxidative damages and senescence in T21 fibroblasts. • Deregulation of miR-155/BAG5/PINK1 and miR-155/CBL axes occurs in T21 fibroblasts. • PLD rescues mitochondrial defects in T21 fibroblasts targeting miR-155. • PLD is proposed as natural drug with the potential to prevent DS-associated comorbidities. - Kidney and urine cell transcriptomics in IgA nephropathy and lupus nephritis: a narrative review
Francesco P Schena, Samantha Chiurlia, Daniela I Abbrescia, Sharon N Cox
Clinical Kidney Journal, 2024
This narrative review sheds light on the use of transcriptomics in the analysis of kidney biopsies and urinary cell samples from patients with immunoglobulin A nephropathy or lupus nephritis. The conventional methods of examining kidney biopsy through light microscopy, immunofluorescence and electron microscopy provide valuable clinical information for diagnosis and prognosis but have some limitations that transcriptomics can address. Some recent studies have reported that kidney transcriptomics has uncovered new molecular biomarkers implicated in the inflammatory process induced by the deposition of circulating immune complexes in the investigated kidney diseases. In addition, transcriptomics applied to urinary cells mirrors the inflammatory process that occurs in the kidney. This means that we can study urinary cell transcriptomics in clinical practice to diagnose the stage of the inflammatory process. Furthermore, the transcriptomics of urinary cells can be used to make therapy decisions during patient follow-up to avoid the stress of a second kidney biopsy. The studies analyzed in this review have a significant limitation. Biomarkers have been identified in small cohorts of patients but none of them has been validated in independent external cohorts. Further prospective studies in large cohorts of patients are necessary for accurate and complete validation. Only after that can these biomarkers be widely used in clinical practice. - Post-hoc analysis of a tool to predict kidney failure in patients with IgA nephropathy
Francesco Paolo Schena, Vito Walter Anelli, Tommaso Di Noia, Giovanni Tripepi, Daniela Isabel Abbrescia, Maria Stangou, Aikaterini Papagianni, Maria Luisa Russo, Graziella D’Arrigo, Carlo Manno
Journal of Nephrology, 2023
BACKGROUND: Recently, a tool based on two different artificial neural networks has been developed. The first network predicts kidney failure (KF) development while the second predicts the time frame to reach this outcome. In this study, we conducted a post-hoc analysis to evaluate the discordant results obtained by the tool. METHODS: The tool performance was analyzed in a retrospective cohort of 1116 adult IgAN patients, as were the causes of discordance between the predicted and observed cases of KF. RESULTS: There was discordance between the predicted and observed KF in 216 IgAN patients (19.35%) all of whom were elderly, hypertensive, had high serum creatinine levels, reduced renal function and moderate or severe renal lesions. Many of these patients did not receive therapy or were non-responders to therapy. In other IgAN patients the tool predicted KF but the outcome was not reached because patients responded to therapy. Therefore, in the discordant group (prediction did not match the observed outcome) the proportion of patients having or not having KF was strongly associated with treatment (P < 0.0001). CONCLUSIONS: The post-hoc analysis shows that discordance in a low number of patients is not an error, but rather the effect of positive response to therapy. Thus, the tool could both help physicians to determine the prognosis of the disease and help patients to plan for their future. - Molecular Profiling of Tissue Samples with Chronic Rejection from Patients with Chronic Lung Allograft Dysfunction: A Pilot Study in Cystic Fibrosis Patients
Francesca Lunardi, Daniela Isabel Abbrescia, Luca Vedovelli, Federica Pezzuto, Francesco Fortarezza, Giovanni Maria Comacchio, Vincenza Guzzardo, Pia Ferrigno, Monica Loy, Chiara Giraudo, Anna Sara Fraia, Eleonora Faccioli, Fausto Braccioni, Emanuele Cozzi, Dario Gregori, Geert M. Verleden, Fiorella Calabrese, Francesco Paolo Schena, Federico Rea
Biomolecules, 2023
Chronic rejection (CR) is the main culprit for reduced survival and quality of life in patients undergoing lung transplantation (Ltx). High-throughput approaches have been used to unveil the molecular pathways of CR, mainly in the blood and/or in bronchoalveolar lavage. We hypothesized that a distinct molecular signature characterizes the biopsies of recipients with clinically confirmed histological signs of CR. Eighteen cystic fibrosis patients were included in the study and RNA sequencing was performed in 35 scheduled transbronchial biopsies (TBBs): 5 with acute cellular rejection, 9 with CR, and 13 without any sign of post-LTx complication at the time of biopsy; 8 donor lung samples were used as controls. Three networks with 33, 26, and 36 differentially expressed genes (DEGs) were found in TBBs with CR. Among these, seven genes were common to the identified pathways and possibly linked to CR and five of them (LCN2, CCL11, CX3CL1, CXCL12, MUC4) were confirmed by real-time PCR. Immunohistochemistry was significant for LCN2 and MUC4. This study identified a typical gene expression pattern in TBBs with histological signs of CR and the LCN2 gene appeared to play a central role. Thus, it could be crucial in CR pathophysiology. - Correction to: Prediction of chronic kidney disease and its progression by artificial intelligence algorithms (Journal of Nephrology, (2022), 35, 8, (1953-1971), 10.1007/s40620-022-01302-3)
Francesco Paolo Schena, Vito Walter Anelli, Daniela Isabel Abbrescia, Tommaso Di Noia
Journal of Nephrology, 2022 - Prediction of chronic kidney disease and its progression by artificial intelligence algorithms
Francesco Paolo Schena, Vito Walter Anelli, Daniela Isabel Abbrescia, Tommaso Di Noia
Journal of Nephrology, 2022
BACKGROUND AND OBJECTIVE: Aim of nephrologists is to delay the outcome and reduce the number of patients undergoing renal failure (RF) by applying prevention protocols and accurately monitoring chronic kidney disease (CKD) patients. General practitioners and nephrologists are involved in the first and in the late stages of the disease, respectively. Early diagnosis of CKD is an important step in preventing the progression of kidney damage. Our aim was to review publications on machine learning algorithms (MLAs) that can predict early CKD and its progression. METHODS: We conducted a systematic review and selected 55 articles on the application of MLAs in CKD. PubMed, Medline, Scopus, Web of Science and IEEE Xplore Digital Library of the Institute of Electrical and Electronics Engineers were searched. The search terms were chronic kidney disease, artificial intelligence, data mining and machine learning algorithms. RESULTS: MLAs use enormous numbers of predictors combining them in non-linear and highly interactive ways. This ability increases when new data is added. We observed some limitations in the publications: (i) databases were not accurately reviewed by physicians; (ii) databases did not report the ethnicity of the patients; (iii) some databases collected variables that were not important for the diagnosis and progression of CKD; (iv) no information was presented on the native kidney disease causing CKD; (v) no validation of the results in external independent cohorts was provided; and (vi) no insights were given on the MLAs that were used. Overall, there was limited collaboration among experts in electronics, computer science and physicians. CONCLUSIONS: The application of MLAs in kidney diseases may enhance the ability of clinicians to predict CKD and RF, thus improving diagnostic assistance and providing suitable therapeutic decisions. However, it is necessary to improve the development process of MLA tools. - Artificial intelligence in glomerular diseases
Francesco P. Schena, Riccardo Magistroni, Fedelucio Narducci, Daniela I. Abbrescia, Vito W. Anelli, Tommaso Di Noia
Pediatric Nephrology, 2022 - Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy
Francesco P Schena, Giovanni Tripepi, Michele Rossini, Daniela I Abbrescia, Carlo Manno
Clinical Kidney Journal, 2022
Background Randomized controlled trials (RCTs) have been conducted, stratifying idiopathic immunoglobulin A nephropathy (IgAN) patients based on the laboratory findings [serum creatinine, estimated glomerular filtration rate (eGFR) and daily proteinuria]. In contrast, data from kidney biopsy have been used only for clinical diagnosis. Therefore, IgAN patients with active or chronic renal lesions have been receiving the same therapy in experimental and control arms of randomized clinical trials (RCTs). Methods Our clinical study of IgAN (CLIgAN) is a multicentre, prospective, controlled and open-label RCT based on patients’ stratification at the time of their kidney biopsy. We will consider, first, the type of renal lesions, followed by serum creatinine values, eGFR and proteinuria. Primary and secondary endpoints will be monitored. Then, we will determine whether personalized therapy can slow the decline of renal function and delay end-stage kidney disease. Results We will enrol 132 IgAN patients with active renal lesions (66 patients per arm) in the first RCT (ACIgAN). They will receive corticosteroids combined with renin–angiotensin system blockers (RASBs) or only RASBs. A total of 294 IgAN patients with chronic or moderate renal lesions at high or very high risk of chronic kidney disease (147 patients per arm) will be enrolled in the second RCT (CHRONIgAN), in which they will receive dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, combined with RASBs, or RASBs alone. Conclusion Using this approach, we hypothesize that patients could receive personalized therapy based on renal lesions to ensure that the right drug gets to the right patient at the right time. - Erratum: Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy (Clinical Kidney Journal DOI: 10.1093/ckj/sfab263)
Francesco P Schena, Giovanni Tripepi, Michele Rossini, Daniela I Abbrescia, Carlo Manno
Clinical Kidney Journal, 2022
[This corrects the article DOI: 10.1093/ckj/sfab263.]. - The molecular mechanisms of inflammation and scarring in the kidneys of immunoglobulin A nephropathy: Gene involvement in the mechanisms of inflammation and scarring in kidney biopsy of IgAN patients
Francesco Paolo Schena, Michele Rossini, Daniela Isabel Abbrescia, Gianluigi Zaza
Seminars in Immunopathology, 2021 - Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy
Francesco Paolo Schena, Vito Walter Anelli, Joseph Trotta, Tommaso Di Noia, Carlo Manno, Giovanni Tripepi, Graziella D’Arrigo, Nicholas C. Chesnaye, Maria Luisa Russo, Maria Stangou, Aikaterini Papagianni, Carmine Zoccali, Vladimir Tesar, Rosanna Coppo, V. Tesar, D. Maixnerova, S. Lundberg, L. Gesualdo, F. Emma, L. Fuiano, G. Beltrame, C. Rollino, R. Coppo, A. Amore, R. Camilla, L. Peruzzi, M. Praga, S. Feriozzi, R. Polci, G. Segoloni, L. Colla, A. Pani, A. Angioi, L. Piras, J. Feehally, G. Cancarini, S. Ravera, M. Durlik, E. Moggia, J. Ballarin, S. Di Giulio, F. Pugliese, I. Serriello, Y. Caliskan, M. Sever, I. Kilicaslan, F. Locatelli, L. Del Vecchio, J.F.M. Wetzels, H. Peters, U. Berg, F. Carvalho, A.C. da Costa Ferreira, M. Maggio, A. Wiecek, M. Ots-Rosenberg, R. Magistroni, R. Topaloglu, Y. Bilginer, M. D’Amico, M. Stangou, F. Giacchino, D. Goumenos, M. Papasotiriou, K. Galesic, L. Toric, C. Geddes, K. Siamopoulos, O. Balafa, M. Galliani, P. Stratta, M. Quaglia, R. Bergia, R. Cravero, M. Salvadori, L. Cirami, B. Fellstrom, H. Kloster Smerud, F. Ferrario, T. Stellato, J. Egido, C. Martin, J. Floege, F. Eitner, T. Rauen, A. Lupo, P. Bernich, P. Menè, M. Morosetti, C. van Kooten, T. Rabelink, M.E.J. Reinders, J.M. Boria Grinyo, S. Cusinato, L. Benozzi, S. Savoldi, C. Licata, M. Mizerska-Wasiak, M. Roszkowska-Blaim, G. Martina, A. Messuerotti, A. Dal Canton, C. Esposito, C. Migotto, G. Triolo, F. Mariano, C. Pozzi, R. Boero, Mazzucco, C. Giannakakis, E. Honsova, B. Sundelin, A.M. Di Palma, F. Ferrario, E. Gutiérrez, A.M. Asunis, J. Barratt, R. Tardanico, A. Perkowska-Ptasinska, J. Arce Terroba, M. Fortunato, A. Pantzaki, Y. Ozluk, E. Steenbergen, M. Soderberg, Z. Riispere, L. Furci, D. Orhan, D. Kipgen, D. Casartelli, D. GalesicLjubanovic, H. Gakiopoulou, E. Bertoni, P. Cannata Ortiz, H. Karkoszka, H.J. Groene, A. Stoppacciaro, I. Bajema, J. Bruijn, X. FulladosaOliveras, J. Maldyk, E. Ioachim, Daniela Abbrescia, Nikoleta Kouri, Maria Stangou, Aikaterini Papagianni, Francesco Scolari, Elisa Delbarba, Mario Bonomini, Luca Piscitani, Giovanni Stallone, Barbara Infante, Giulia Godeas, Desiree Madio, Luigi Biancone, Marco Campagna, Gianluigi Zaza, Isabella Squarzoni, Concetta Cangemi
Kidney International, 2021 - The assessment of the level and of the intellectual qualities at the expert level. The contribution of two psychodiagnostic tools: The wechsler scales and the Raven matrices
I. Grattagliano, Abbrescia Daniela, A. D. Conza, L. L. Bianco, Massaro Ylenia, Parisi Davide, S. Tafuri, R. Catanesi
Rassegna Italiana Di Criminologia, 2020 - TRIM8 Blunts the Pro-proliferative Action of ΔNp63α in a p53 Wild-Type Background
Mariano Francesco Caratozzolo, Flaviana Marzano, Daniela Isabel Abbrescia, Francesca Mastropasqua, Vittoria Petruzzella, Viola Calabrò, Graziano Pesole, Elisabetta Sbisà, Luisa Guerrini, Apollonia Tullo
Frontiers in Oncology, 2019 - Plasma β-amyloid 1–42 reference values in cognitively normal subjects
Chiara Zecca, Rosanna Tortelli, Francesco Panza, Simona Arcuti, Marco Piccininni, Rosa Capozzo, Maria Rosaria Barulli, Roberta Barone, Roberta Cardinali, Daniela Abbrescia, Davide Seripa, Vincenzo Brescia, Giancarlo Logroscino
Journal of the Neurological Sciences, 2018 - Social dysfunction in older age and relationships with cognition, depression, and apathy: The GreatAGE Study
Madia Lozupone, Francesco Panza, Marco Piccininni, Massimiliano Copetti, Rodolfo Sardone, Bruno P. Imbimbo, Eleonora Stella, Francesca D’Urso, Maria Rosaria Barulli, Petronilla Battista, Alessandra Grasso, Rosanna Tortelli, Rosa Capozzo, Francesco Coppola, Daniela Isabel Abbrescia, Antonello Bellomo, Gianluigi Giannelli, Nicola Quaranta, Davide Seripa, Giancarlo Logroscino
Journal of Alzheimer S Disease, 2018 - Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging
Vincenzo Solfrizzi, Emanuele Scafato, Madia Lozupone, Davide Seripa, Michele Giannini, Rodolfo Sardone, Caterina Bonfiglio, Daniela I. Abbrescia, Lucia Galluzzo, Claudia Gandin, Marzia Baldereschi, Antonio Di Carlo, Domenico Inzitari, Antonio Daniele, Carlo Sabbà, Giancarlo Logroscino, Francesco Panza, E. Scafato, G. Farchi, L. Galluzzo, C. Gandin, A. Capurso, F. Panza, V. Solfrizzi, V. Lepore, P. Livrea, L. Motta, G. Carnazzo, M. Motta, P. Bentivegna, S. Bonaiuto, G. Cruciani, D. Postacchini, D. Inzitari, L. Amaducci, A. Di Carlo, M. Baldereschi, C. Gandolfo, M. Conti, N. Canal, M. Franceschi, G. Scarlato, L. Candelise, E. Scapini, F. Rengo, P. Abete, F. Cacciatore, G. Enzi, L. Battistin, G. Sergi, G. Crepaldi, S. Maggi, N. Minicucci, M. Noale, F. Grigoletto, E. Perissinotto, P. Carbonin
American Journal of Geriatric Psychiatry, 2017 - Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD)
Maria Notarnicola, Maria Gabriella Caruso, Valeria Tutino, Caterina Bonfiglio, Raffaele Cozzolongo, Vito Giannuzzi, Valentina De Nunzio, Giampiero De Leonardis, Daniela I. Abbrescia, Isabella Franco, Vincenza Intini, Antonella Mirizzi, Alberto R. Osella
Lipids in Health and Disease, 2017 - Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial
G. Misciagna, M. del Pilar Díaz, D. V. Caramia, C. Bonfiglio, I. Franco, M. R. Noviello, M. Chiloiro, D. I. Abbrescia, A. Mirizzi, M. Tanzi, M. G. Caruso, M. Correale, R. Reddavide, R. Inguaggiato, A. M. Cisternino, Alberto Rubén Osella
Journal of Nutrition Health and Aging, 2017 - Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review
Vincenzo Solfrizzi, Carlo Custodero, Madia Lozupone, Bruno P. Imbimbo, Vincenzo Valiani, Pasquale Agosti, Andrea Schilardi, Alessia D’Introno, Maddalena La Montagna, Mariapaola Calvani, Vito Guerra, Rodolfo Sardone, Daniela I. Abbrescia, Antonello Bellomo, Antonio Greco, Antonio Daniele, Davide Seripa, Giancarlo Logroscino, Carlo Sabbá, Francesco Panza
Journal of Alzheimer S Disease, 2017 - Stimulation by pro-apoptotic valinomycin of cytosolic NADH/cytochrome c electron transport pathway - Effect of SH reagents
Dario Domenico Lofrumento, Gianluigi La Piana, Valeria Palmitessa, Daniela Isabel Abbrescia, Nicola Elio Lofrumento
International Journal of Biochemistry and Cell Biology, 2016 - Site-dependent biological activity of valinomycin analogs bearing derivatizable hydroxyl sites
Cosimo Annese, Daniela I. Abbrescia, Lucia Catucci, Lucia D'Accolti, Nunzio Denora, Immacolata Fanizza, Caterina Fusco, Gianluigi La Piana
Journal of Peptide Science, 2013 - Malate-aspartate shuttle and exogenous NADH/cytochrome c electron transport pathway as two independent cytosolic reducing equivalent transfer systems
Daniela Isabel Abbrescia, Gianluigi La Piana, Nicola Elio Lofrumento
Archives of Biochemistry and Biophysics, 2012 - Valinomycin induced energy-dependent mitochondrial swelling, cytochrome c release, cytosolic NADH/cytochrome c oxidation and apoptosis
Dario Domenico Lofrumento, Gianluigi La Piana, Daniela Isabel Abbrescia, Valeria Palmitessa, Velia La Pesa, Domenico Marzulli, Nicola Elio Lofrumento
Apoptosis, 2011 - Ceramide-induced activation of cytosolic NADH/cytochrome c electron transport pathway: An additional source of energy for apoptosis
Vincenza Gorgoglione, Valeria Palmitessa, Dario Domenico Lofrumento, Gianluigi La Piana, Daniela Isabel Abbrescia, Domenico Marzulli, Nicola Elio Lofrumento
Archives of Biochemistry and Biophysics, 2010
